B
BlackThorn Therapeutics
Precision therapeutics for central nervous system disorders
About BlackThorn Therapeutics
BlackThorn Therapeutics was a clinical-stage biopharmaceutical company that focused on creating targeted therapeutics for neurobehavioral disorders. Founded around 2013-2015, the company was a spinout from The Scripps Research Institute. The founding scientific team included individuals such as Alex Tkachenko, Bill Martin, Ed Roberts, and Hugh Rosen. BlackThorn aimed to address the historical challenges in neuropsychiatric drug development, such as patient heterogeneity, by using a data-driven approach.
The company's core was its proprietary cloud-based computational psychiatry platform, known as PathFinder™ or INFORM. This platform integrated and analyzed multimodal data, including brain imaging and objective behavioral assessments, to identify dysfunctional brain circuits and objective neuromarkers. By doing so, BlackThorn sought to identify specific, biologically-based patient subgroups most likely to respond to a particular treatment, thus bringing a precision medicine approach to brain disorders. This strategy was intended to increase the probability of clinical trial success.
BlackThorn's business model was centered on advancing its pipeline of small-molecule drug candidates through clinical trials. The company raised significant capital, including a $40 million Series A in 2016 and a $76 million Series B in 2019, from prominent investors like ARCH Venture Partners, GV (formerly Google Ventures), and Johnson & Johnson Innovation. Its pipeline included several drug candidates targeting various receptors linked to neurobehavioral disorders. One lead program, BTRX-335140 (later navacaprant or NMRA-140), was a kappa opioid receptor (KOR) antagonist developed for major depressive disorder. Another program, BTRX-323511, was a vasopressin 1a receptor antagonist for conditions like autism spectrum disorder.
In 2020, BlackThorn Therapeutics was acquired by Neumora Therapeutics and became a foundational part of the new, larger company. Neumora, which launched in 2021 with $500 million in financing, integrated BlackThorn's team, platform, and clinical-stage assets to continue the mission of developing precision medicines for brain diseases. BlackThorn's lead drug candidates continued their development under Neumora's stewardship.
Source: Dealroom company dataAt a glance
- Status
- Closed
- Employees
- 2
- Open positions
- None listed
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Developer Tools, Biotechnology, Drug Development, Mental Health, Core AI, Spinout, Tech for Biotech and Pharma, Biotech and Pharma
- Technology
- Artificial Intelligence
- Business model
- Manufacturing
- Client focus
- B2C
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Jun 2019 | $76M | $304M | Polaris Partners · Vertex Holdings · Premier Partners · Altitude Life Science Ventures | — |
| GRANTOther financing | Jun 2017 | $8M | — | National Institute of Neurological Disorders and Stroke | — |
Growth signals
Latest recorded traffic for BlackThorn Therapeutics is 260 monthly website visits, down 61.2% over the last three months. BlackThorn Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
BlackThorn Therapeutics in the San Francisco ecosystem
The BlackThorn Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
National Institute of Neurological Disorders and Stroke
Series A11 investors entered at this stage
ARCH Venture Partners
Altitude Life Science Ventures
Johnson & Johnson Innovation
Alexandria Equities
Mercury Fund
GV
Biomatics Capital Partners
Polaris Partners
Vertex Holdings
Premier Partners
Alexandria Venture Investments
Other known investors1 additional known investor
Scripps Translational Science Institute
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about BlackThorn Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BlackThorn Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









